1. Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast Cancer: A Multidisciplinary Stepwise Approach for Prevention, Early Detection, and Treatment.
- Author
-
Mauro, Ciro, Capone, Valentina, Cocchia, Rosangela, Cademartiri, Filippo, Riccardi, Ferdinando, Arcopinto, Michele, Alshahid, Maie, Anwar, Kashif, Carafa, Mariano, Carbone, Andreina, Castaldo, Rossana, Chianese, Salvatore, Crisci, Giulia, D'Assante, Roberta, De Luca, Mariarosaria, Franzese, Monica, Galzerano, Domenico, Maffei, Vincenzo, Marra, Alberto M., and Valente, Valeria
- Subjects
EPIDERMAL growth factor receptors ,CANCER patients ,BREAST cancer ,ANTHRACYCLINES ,DAUNOMYCIN - Abstract
Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality affecting life expectancy amongst cancer survivors. In recent years, because of the possibility of early diagnosis and the increased efficacy of neo-adjuvant and adjuvant systemic treatments (targeting specific molecular pathways), the high percentage of survival from breast cancer led CVD to become the first cause of death among survivors. Therefore, it is mandatory to adopt cardioprotective strategies to minimize CV side effects and CVD in general in breast cancer patients. Cancer therapeutics-related cardiac dysfunction (CTRCD) is a common group of side effects of chemotherapeutics widely employed in breast cancer (e.g., anthracycline and human epidermal growth factor receptor 2 inhibitors). The aim of the present manuscript is to propose a pragmatic multidisciplinary stepwise approach for prevention, early detection, and treatment of cardiotoxicity in patients with breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF